A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Trial Profile

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms EMPEROR-Preserved
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 25 Apr 2018 According to the Boehringer Ingelheim media release, this trial expected to read out between 2019 and 2020.
    • 17 Mar 2018 According to a Boehringer Ingelheim media release, EMPEROR HF clinical trial programme will investigate once daily empagliflozin, compared to placebo, the programme comprises two Phase III, trials which assess heart failure in patients with preserved ejection fraction (NCT03057951) or patients with reduced ejection fraction (NCT03057977).
    • 17 Mar 2017 Status changed from not yet recruiting to recruiting, according to a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top